Database

IN CELL ART

Solution provided
Technology
Supplier identity
General description

Founded by a research team including a Nobel laureate, InCellArt
has designed new classes of versatile vectors, organized at the
nanometric scale, enabling macromolecules to cross the cell
barrier efficiently and safely and to be targeted to the site or organ
where they are active.

Type of Supplier
Biotechnology R&D Company - Diagnostics / Devices and Diagnostics ServicesBiotechnology Company - Therapeutics
Region
Regions of Pays de la Loire, Centre and Poitou-Charentes, FR
Regional access broker
  • Grégory Bauer, Atlanpole Biotherapies
Activity description
The 3 top equipments available

ICANtibodies™ is a fully integrated process from DNA antigen design and synthesis, nanotaxi/DNA formulation and immunization in various species
including mice, rats, rabbits and goats, to antibody quality controls. In the absence of recombinant protein, InCellArt patented
Nanotaxi allows for the development of functional antibodies against any natively-expressed antigen. InCellArt has achieved an
important technological breakthrough and is now able to produce novel antibodies against membrane targets as well as intracellular,
nuclear and secreted antigens. To date, we have been successful in generating antibodies against antigens originating from various
species and localizations. We have a proven track record with more than 200 different antibodies produced in less than 36 months.

ICA Nanocarriers DNA Vaccine
ICA614 nanocarrier, an innovative DNA synthetic formulation, offers unique efficient and industrial features such as the dramatic
enhancement of the immunogenicity of plasmid DNA-encoding tumours or pathogen-derived antigens, a reduction in the dose of
plasmid DNA, as well as an excellent safety profile. ICA614 nanocarrier represents a crucial step in DNA vaccine development, and is
currently being tested by major vaccine companies (SANOFI-PASTEUR, MERIAL…).
mRNA Vaccine
Some other ICA nanocarriers are also being assessed in $33.1 million RN-ARMORVAX consortium, co-funded by US Defense Advanced
Research Projects Agency (DARPA). The consortium would validate the new application of ICA nanocarriers for mRNA-based vaccines
for infectious diseases.

ICAFectin®441 and ICAFectin®442
DNA and siRNA transfection reagents are novel synthetic molecules derived from natural compounds and specifically designed to
provide the best, safe, efficient transfection solution in almost any cells. ICAFectin®441 and ICAFectin®442 transfection reagents
are becoming the reagents-of-choice for efficient DNA and siRNA transfections, as demonstrated by increased use in numerous
studies published in high-impact-factor journals, including Journal of Biological Chemistry, Nucleic Acids Research, PLOS ONE, PLOS
Pathogen, Human Gene Therapy, Journal of Neurochemistry, Experimental Cell Research, Neoplasia…

Training and Staff possibilities
No
Contact information
Name
BELLOCQ
Surname
Chloé
Function
CEO
Address
Halle 13 Bio-Ouest
21 Rue La Noue Bras-de-Fer
44200  Nantes
France